1. INTRODUCTION {#sec1}
===============

Neurodegenerative disorders such as Alzheimer disease (AD), Parkinson disease (PD), frontotemporal degeneration, prion, Huntington, and motoneuron diseases are increasingly being realized to have common cellular and molecular mechanisms including protein aggregation and inclusion body formation in selected areas of the nervous system. Therefore, these disorders are summarized as "proteinopathies" \[[@B1], [@B2]\]. The aggregations usually consist of insoluble fibrillary aggregates containing misfolded protein with *β*-sheet formation. The most probable explanation is that these inclusions and aggregates symbolize an end stage of a molecular cascade of complicated events, and that an earlier stage may be more directly tied up to the---hitherto unknown---pathogenesis of the disorder than the inclusions themselves, which may or may not represent diagnostic hallmarks. Small intermediates termed as "soluble oligomers" in the aggregation process may influence synaptic dysfunction, while large insoluble deposits might function as reservoirs of the bioactive oligomers that can lead to synaptic dysfunction, neuronal apoptosis, and brain damage \[[@B3], [@B4]\]. This is predominantly due to iron-related oxidative damage mediated by *α*-synuclein (*α*Syn) oligomerisation during the development of PD pathology \[[@B5]\]. Seeding induced by *α*Syn oligomers, the toxicity of which has been demonstrated *in vivo* \[[@B6]\], can induce intracellular *α*Syn aggregation, providing evidence for spreading of *α*Syn pathology \[[@B7]\] similar to that of prions \[[@B8]\]. Amyloid-*β* (A*β*) induces the neurodegenerative triad of spine loss, dendritic changes, and neuritic dystrophies through calcineurin activation \[[@B9]\], while soluble tau species rather than aggregated ones induce neurodegeneration \[[@B10]\]. Tau phosphorylation proceeds to tau aggregation that is favored by kinases like glucose-synthase kinase-3*β* (GSK-3*β*) \[[@B11]\], while inhibition of GSK-3*β* activity prevented not only tau phosphorylation but also tau aggregation in hippocampus \[[@B12]\]. Recent studies showed that caspase activation, observed in a tg mouse model overexpressing GSK-3*β* \[[@B13]\], precedes tangle formation \[[@B14]\]. Seeding of normal tau by pathological tau conformers further drives pathogenesis of neurofibrillary tangles (NFT) \[[@B15]\]. However, the mechanism by which oligomers trigger neurodegeneration still remains elusive. The aim of this paper is to review the molecular mechanisms and interactions between the various pathological proteins in neurodegeneration.

2. INTERACTION BETWEEN *α*Syn, Tau, AND AMYLOID-*β* IN PARKINSON DISEASE {#sec2}
========================================================================

Intracytoplasmic proteinaceous inclusions, primarily composed of tau and/or *α*Syn, are predominant pathological features of AD and PD, respectively \[[@B16]\]. However, the coexistence of these and other pathological proteinaceous aggregates like A*β* is identified in many neurodegenerative disorders \[[@B17]--[@B19]\]. The cooccurrence of both *α*Syn and tau or other pathologic proteins highlights the interface between them \[[@B20]\]. They may be coaggregated in the same brain or even in the same region or in the same cell in human brains \[[@B18], [@B21], [@B22]\] and transgenic mice \[[@B23]\]. Whereas *α*Syn can spontaneously polymerize into amyloidogenic fibrils, *in vitro*, tau polymerization requires an inducing agent \[[@B24]\]. Cellular models, various transgenic and other experimental PD models, provided novel insights into the role of *α*Syn in the hyperphosphorylation of tau protein observed in disease \[[@B24]--[@B32]\]. These data suggest that oxidatively modified *α*Syn is degraded by the proteasome and plays a proaggregatory role for tau \[[@B31]\], and that *α*Syn is an *in vivo* regulator of tau protein phosphorylation at Ser (262). Toxic interactions with *α*Syn may lead to hyperphosphorylation of tau and eventually to the deposition of both proteins in the disease \[[@B33]\]. E46K human *α*Syn tg mice develop Lewy-like and tau pathology associated with age-dependent motor impairments, supporting the notion that *α*Syn is involved in the pathogenesis of human diseases \[[@B34]\].

Recent postmortem studies showed increased accumulation of tau protein phosphorylated at Ser 262 and 396/404 in the striata of PD patients and in the A53T *α*Syn mutant mouse model of PD \[[@B27], [@B35]\]. This is related to increased activity of GSK-3*β* \[[@B26], [@B29]\], a major kinase that hyperphosphorylates tau to produce pathologic forms of tau \[[@B36]\] and may be a possible link between A*β* and tau \[[@B37], [@B38]\]. Dopamine D1 receptor activation induces tau phosphorylation via cyclin-dependent kinase 5 (cdk5) and GSK-3*β* signaling pathways \[[@B39]\]. Expression of both GSK-3*β* and microtubule-associated protein/microtubule affinity-regulating kinase 2 inhibited the formation of *α*Syn-induced tau aggregation \[[@B24]\]. Reduced 19S and 20S proteasomal subunit activites in PD striata suggest that they account for the abnormal disposal of *α*Syn and phosphorylated tau (p-tau). The small decrease in proteasomal activity in PD striata is consistent with other studies that showed no significant changes of these proteins in PD striata but lower activity in substantia nigra (SN) \[[@B40]\]. In an MPTP model and in MPP+ cellular models, *α*Syn has been shown to induce GSK-3*β*-catalyzed tau phosphorylation \[[@B41]--[@B43]\]. PD-associated risk factors such as environmental toxins and *α*Syn mutations promote tau phosphorylation at Ser 262, causing microtubule instability, which leads to neuronal degeneration \[[@B30]\]. Rotenon exposure may also induce *α*Syn and A*β* aggregation as well as increased hyperphosphorylation of tau, although high concentrations of the pesticide lead to cell death before protein aggregation \[[@B32]\].

Tau in MPTP models and in human postmortem PD striata is hyperphosphorylated at the same sites (Ser 202, 262, and 396/404) as in AD \[[@B35]\], whereas phosphorylation of soluble tau differs in AD and Pick disease brains \[[@B44]\]. Tauopathy in PD striata is restricted to dopaminergic neurons, whereas degeneration in the inferior frontal cortex, associated with increased tau deposition because of diminished proteasomal activity in the absence of oxidative stress and pGSK-3*β* activity, is not associated with tauopathy \[[@B35]\]. In the *α*Syn overexpressing mouse model of PD tauopathy, along with microtubule destabilization, exists primarily in the brainstem and striatum, the two major brain regions known to express high levels of *α*Syn and undergo the highest levels of degeneration in human PD. Thus, tauopathy in PD may have a restricted pattern of distribution \[[@B28]\], which differs from its generalized affection in AD. Whether there are differences in the 3- and 4-repeat tau pathology between these disorders is not yet fully understood and needs further investigation.

There is strong interaction between *α*Syn, tau, and A*β*, particularly in their oligomeric forms, which might synergistically promote their mutual aggregation and vice versa \[[@B33], [@B45], [@B46]\]. Cross-seeding between dissimilar proteins that share *β*-sheet structures has been described, for example, of A*β* and *α*Syn \[[@B47]\], tau and *α*Syn \[[@B48]\], and prion protein and A*β* \[[@B49]\]. *In vivo* interactions between *α*Syn and tau are supported by genetic studies \[[@B50], [@B51]\], and in familial PD, fibrillation of *α*Syn and tau is caused by the A 53T mutation \[[@B48]\]. A family with early onset dementia was pathologically characterized by widespread appearance of LBs and NFTs, but no amyloid deposits \[[@B52]\]. Recent studies gave evidence that prions trigger hyperphosphorylation of tau in genetic, sporadic, and transmitted forms of prion diseases in the absence of amyloid plaques \[[@B53]\].

Neurofibrillary tau pathology is modulated by genetic variations of *α*Syn \[[@B54]\]. Tau phosphorylation is found in synapse-enriched fractions of frontal cortex in PD and AD \[[@B55]\] and in brainstems of *α*Syn mice \[[@B56]\]. Other links between *α*Syn and tau are suggested by the colocalization of both proteins in both NFTs and Lewy bodies (LBs), especially in neuronal populations vulnerable for both aggregates \[[@B21], [@B57]--[@B59]\], in the olfactory bulb in AD with amygdaloid LBs \[[@B57]\], and in neuronal and glial cytoplasmic inclusions in multiple system atrophy (MSA) \[[@B60], [@B61]\]. Between 15 and 60% of AD brains show numerous *α*Syn lesions in the amygdala, even in the absence of subcortical LBs \[[@B62], [@B63]\]. AD with amygdala LBs is considered a distinct form of *α*-synucleinopathy \[[@B64]\]. In AD patients with clinical extrapyramidal symptoms, between 50 and 88% of the patients showed extensive *α*Syn pathology co-localized with p-tau in SN, tau and less *α*Syn pathology in brainstem significantly increasing with higher neuritic Braak stages \[[@B65]--[@B67]\].

In conclusion, genetic, pathologic, and biochemical evidence support a role for tau in the pathogenesis of PD \[[@B33]\], and concurrence of tau, *α*Syn, and TDP-43 pathology in brains of AD and LB disease provide a better understanding of the pathogenic pathways in these disorders \[[@B17]\]. It has been suggested that the process of LB formation is triggered, at least in part, by Alzheimer pathology \[[@B18], [@B68]\], while the interaction between *α*Syn and tau in MSA awaits further elucidation \[[@B61], [@B69]\]. Recent data suggest that PD and AD could be linked by progressive accumulation of p-tau, activated GSK-3*β*, and *α*Syn \[[@B27], [@B35], [@B70a], [@B70b]\], while activation of caspase and caspase-cleft Δtau may represent a common way of abnormal intracellular accumulation of both tau and *α*Syn, promoted by A*β* deposition, unifying the pathology of AD and LB diseases \[[@B71]--[@B73]\] (see [Figure 1](#fig1){ref-type="fig"}). In addition, emerging evidence suggests that prion-like spreading, evolving secreted proteins such as A*β*, and cytosolic proteins such as tau and *α*Syn are spreading by cell-to-cell transmission, thus unifying the pathogenesis of many neurodegenerative disorders \[[@B8], [@B74]\], but is not fully understood whether they are due to similar protein aggregation and misfolding mechanisms. Combined determination of *α*Syn, tau, and A*β* concentrations in cerebrospinal fluid (CSF) show differential patterns in these neurodegenerative disorders \[[@B75]\]; in particular tau/*α*Syn ratios can contribute to the discrimination of PD \[[@B76]\].

Other studies have suggested that A*β* is more likely to promote the deposition of *α*Syn than tau \[[@B77]\], and A*β* is known to initiate hyperphosphorylation of tau \[[@B78]\]. Cortical *α*Syn load is associated with A*β* plaque burden in a subset of PD patients \[[@B79]\]. A*β* peptides enhance *α*Syn accumulation and neuronal deficits in a tg mouse model \[[@B80]\], and *α*Syn-induced synapse damage is enhanced by A*β* 1-42 \[[@B81]\]. Both can be linked by separate mechanisms driven by a common upstream component \[[@B82]\]. Recent studies showed that A*β* 1-42 tightly binds to tubulin polymerization promoting protein (TPPP/p25) and causes aberrant protein aggregations inhibiting the physiologically relevant TPPP/p25-derived microtubule assembly, the interaction of TPPP/p25 and A*β* can produce pathologic aggregates in AD and LB diseases \[[@B83]\]. These lesions represent a collision of two or more processes, but it is unclear whether there is a common underlying final pathology leading to neuronal degeneration (see \[[@B84]\]) ([Figure 2](#fig2){ref-type="fig"}).

3. AMYLOID-*β* AND Tau IN ALZHEIMER DISEASE {#sec3}
===========================================

The brains in patients with AD, in addition to nerve and synapse loss, are characterized by two hallmark lesions, A*β*-containing plaques and NFT, which are composed of hyperphosphorylated forms of microtubuli-associated protein tau \[[@B85]\]. Progression of NFT pathology throughout the brain correlates with disease progression \[[@B86]\], and loss of synapses is one of the earliest events that has been associated with functional impairment \[[@B87]\]. Although both A*β* and tau have been extensively studied with regard to their separate modes of toxicity (see \[[@B88]\]), more recently new light has been shed on their possible interactions and synergistic effects in AD, linking A*β* and tau \[[@B89], [@B90]\]. Moreover, the interaction between tau and A*β* mediated by FIN kinase should be considered, since it is an interesting link between the two pathogenic hallmarks of the disorders \[[@B36]--[@B38]\].

According to the amyloid cascade hypothesis, A*β* formation is the critical step in diving AD\'s pathogenesis \[[@B91]\]. Support for this concept stems from the identification of pathogenic mutations in patients with familial AD linked to A*β* formation and a higher frequency of AD in people with trisomy 21, who carry an additional APP allele \[[@B92]\].

Although A*β* and tau exert toxicity through separate mechanisms \[[@B93]\], evidence from both *in vitro* and *in vivo* models suggest that there are three possible models of interaction between the two. (1) A*β* drives tau pathology, supported by induction of tau hyperphosphorylation by A*β* formation in APP tg mice \[[@B94]\], induction of neuronal tau hyperphosphorylation by A*β* oligomers \[[@B95]\] and, together with neuritic degeneration, by soluble A*β*-protein dimers isolated from Alzheimer cortex \[[@B96]\], or by A*β*-rich brain extracts \[[@B97]\], and aggravation of NFT pathology by intracranial injection of synthetic A*β* into mutant tau tg mice \[[@B98]\]. On the other hand, a single-dose intraventricular injection of an A*β* antibody in 4-month-old mice cleared intraneuronal A*β* pathology and reduced early cognitive deficits \[[@B99]\], and inhibition of GSK-3*β* attenuated A*β*-induced tau phosphorylation *in vitro* and can reduce tau pathology *in vivo* \[[@B12], [@B100]\]. Other data suggest induction of NFT formation by amyloidogenic peptides rather than specifically by A*β* \[[@B101]\]. While the 3xtg AD mouse model, based on early intraneuronal accumulation of A*β* played an important role in supporting the "intraneuronal A*β* hypothesis" \[[@B99]\], recent evidence claims that these mice early and age-dependently accumulate A*β*PP instead of A*β* within neurons \[[@B102], [@B103]\], thus challenging this hypothesis. (2) Synergistic effects of A*β* and tau by impairment of mitochondrial respiration in triple tg mice that display both A*β* and tau pathologies \[[@B104]\]. This indicates the convergence of A*β* and tau on mitochondrial deterioration and establishes a molecular link in AD pathology *in vivo* \[[@B105], [@B106]\]. (3) Tau mediates A*β* toxicity supported by the observation that tau −/− neurons are protected from A*β* induced cell death in cell culture \[[@B107]--[@B109]\]. Tau reduction also prevents A*β*-induced defects in axonal transport of mitochondria and other cargoes \[[@B110]\], which may link the "tau hypothesis" to other ones, the axonal transport impairment hypothesis, according to which tau induces failure of axonal transport \[[@B111], [@B112]\], and the "oxidative stress hypothesis" according to which mitochondria are functionally impaired, resulting in the production of reactive oxidative species \[[@B113]\]. Astrocytes have been shown to be important mediators of A*β*-induced neurotoxicity and tau hyperphosphorylation in primary cultures \[[@B13]\].

Although knowledge about the roles of tau and its interactions with A*β* is increasing (see \[[@B1], [@B114]\]), many questions about the scaffolding partners for tau in its interaction with A*β* are still unanswered. While this phenomen may result from direct cross-seeding of tau by aggregated A*β* \[[@B115], [@B116]\], indirect pathways such as A*β*-induced tau phosphorylation, inflammation, and/or disruption of proteostasis \[[@B37], [@B90], [@B117]\] have not been ruled out.

As we gain a deeper understanding of the different cellular functions of tau, the focus shifts from the axon, where tau has a principal role as microtubule-associated protein, to the dendrite, where it mediates A*β* toxicity \[[@B90]\]. On the other hand, according to several data, tau aggregates may be a consequence rather than a cause of neurodegeneration \[[@B14], [@B118]\]. Therefore, the effects promoted by A*β* and tau should be analyzed more specifically to identify the mechanisms that underlay A*β* and tau toxicity and/or neuroprotection in order to find appropriate therapeutic targets.

4. INDUCTION AND SPREAD OF PROTEIN AGGREGATES IN NEURODEGENERATIVE DISEASES {#sec4}
===========================================================================

Increasing evidence implicates the importance of disease-specific proteins and their interrelations in various neurodegenerative disorders \[[@B1]--[@B4], [@B16]\]. In PD, *α*Syn-rich lesions that typify Lewy body pathology, first arise in the lower brainstem and in the anterior olfactory nucleus and olfactory bulb; they subsequently appear in a predictable sequence in mesencephalic and neocortical regions \[[@B119]--[@B121]\], although their reliability of Lewy pathology staging in sporadic PD has been a matter of discussion \[[@B122]--[@B125]\]. The concept that *α*Syn lesions ramify within the CNS by a seeding-like process is supported by the observation that fetal dopaminergic transplants in the striatum of a subset of PD patients surviving more than 5 years may develop *α*Syn-positive Lewy bodies \[[@B126]--[@B128]\]. These data imply for a host-to-graft propagation of *α*Syn, but the effects of LBs in the grafted neurons are unclear \[[@B128]\], although neuron-to-neuron (interneuron) transmission or transsynaptic spread of *α*Syn appears a likely interpretation for the propagation of the disease \[[@B8], [@B128]\]. It has been suggested that LBs develop in transplanted dopaminergic neurons in a fashion similar to that in the host SN \[[@B129]\]. On the other hand, LB pathology in grafted neurons does not necessarily mean their functional impairment. Similar accumulation of *α*Syn occurs in stem cells transplanted into transgenic mice \[[@B8]\]. Secreted *α*Syn can recruit endogenous *α*Syn in the recipient cells, act as a permissive template, and promote misfolding in small aggregates \[[@B130]\]. Some of the uptake of *α*Syn from the extracellular space appears to occur via endocytosis, although additional mechanisms might also contribute \[[@B130], [@B131]\]. It is probable to trigger the formation of large LB-like aggregates in cultured cells, when artificial methods, bypassing physiologic uptake mechanisms, are used to promote the entry of misfolded *α*Syn. *In vivo* approaches in cell cultures could not discriminate between a prion-like mechanism---host-derived, misfolded *α*Syn inducing misfolding of *α*Syn generated in the graft---versus simple translocation of aggregated synuclein from the host to the graft. Thus, in cell culture all the mechanisms needed for prion-like behavior of misfolded *α*Syn appear to be in place \[[@B130], [@B132], [@B133]\]. These and other data suggest that *α*Syn pathology could be induced in cells and may spread by a prion like mechanism involving the transmission of conformationally altered *α*Syn \[[@B134]--[@B137]\]. Thus, the prion-like propagation of *α*Syn lesions has been demonstrated as has the induction of proteinaceous lesions associated with other neurodegenerative diseases, such as aggregates of superoxide dismutase 1 (SOD1) \[[@B138], [@B139]\], aggregates of polyamine \[[@B140]\], which typify Huntington disease and spinocerebellar ataxias, or cytosolic aggregates of TDP-43 \[[@B141]\], which are present in ALS and frontotemporal lobar degeneration with TDP-43-positive inclusions (FTDL-TDP). The capability of passing between living cells is not limited to prions and those cited above; it was also shown for aggregates of truncated tau, consisting of the microtubule-binding region and a fluorescent protein tag that can leave and enter cells in culture and promote the aggregates and fibrillization of normal tau within them \[[@B114], [@B142]--[@B145]\]. The recent demonstration of tau-positive pretangle material in the locus ceruleus before involvement of the transentorhinal region of the cerebral cortex in young individuals \[[@B146]\] suggests a progression of tau pathology via neuron-to-neuron transmission and transsynaptic transport of tau protein aggregates \[[@B147]\], since seeding of neuronal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles \[[@B15]\]. These data may indicate that the currently used neuropathological stages of AD \[[@B148]--[@B150]\] will have to be reclassified. Mutant P201S tau, as found in frontotemporal dementia with parkinsonism (FDTP-19), is capable of spreading through the cortex of an Alz 17 tg mouse expressing the human wild type protein and induce an NFT-like pathology that consists of human tau in brain areas distant from the injection site \[[@B144]\]. These and other data raise the possibility that neurodegenerative pathologies could spread within the brain via a mechanism analogous to prion-like self-propagation, although alternative mechanisms, such as disruption of basic cellular proteostasis by exogenous aggregates, cannot be excluded \[[@B151]\]. Furthermore, tau and *α*Syn are present in blood and CSF in both monomeric and oligomeric forms, suggesting release of these normally intracellular proteins *in vivo* \[[@B76], [@B152]--[@B154]\]. The intercellular transfer of cytosolic protein aggregates may also occur through nanotubes, exosomes, or microvesicles \[[@B134]\]. Like other pathogenic proteins, A*β* can be taken up, modified, and secreted by cells *in vitro* \[[@B107], [@B155]\], and it is also present in the CSF \[[@B156]\].

5. CONCLUSIONS {#sec5}
==============

Interaction between *α*Syn, tau, and A*β* may be a molecular mechanism in the overlapping pathology of LB disease and AD, possibly representing a complex continuum, characterized by variable amounts of pathologic proteins, and A*β* is suggested to promote accumulation of both *α*Syn and tau; the procession from A*β* to neurite pathology in the cerebral cortex of AD and DLB may be unifiable \[[@B72], [@B73]\]. DLB-3xtg-AD mice exhibit accelerated formation of *α*Syn and LB-like inclusions in the cortex and enhanced increase of p-tau deposits immunoreactive for antibody AT8 in the hippocampus, and neocortex provide further evidence that tau, *α*Syn, and A*β* interact *in vivo* to promote accumulation of each other and accelerate cognitive dysfunction, although accumulation of *α*Syn alone can significantly disrupt cognition \[[@B157], [@B158]\]. Polymorphic tau and A*β*-tau aggregates may be due to repeated sequences, which are prone to variable turn locations along the tau repeats, suggesting that synergistic interactions between repeats in tau protein and A*β* may be responsible for accelerated aggregation via polymorphic states \[[@B116]\]. These changes and common inflammatory mechanisms in these disorders \[[@B159]\] could be generated by the same stimulus, with the outcome possibly having an inverse relationship depending on genetic backgrounds and environmental factors. Although recent data documented colocalization of *α*Syn and tau in LBs \[[@B57]\], of A*β* and p-tau in synaptosomes \[[@B160]\], synaptic terminals \[[@B161]\], and in triple transgenic mice \[[@B104]\], why tau, A*β*, and *α*Syn pathologies are so intimately associated remains one of the major questions of the pathogenesis of neurodegeneration in selected/vulnerable brain regions that are typical for different disease processes (double or triple amyloidoses). It has been suggested that these pathologies represent a common final pathway leading to or preventing neuronal damage \[[@B23], [@B70a], [@B70b], [@B84]\]. The basic molecular mechanisms (presumed regional differences in proteasomal, caspase, GSK-3*β* activities, oxidative stress in the presence of *α*Syn deposition, etc.) need further elucidation, and the molecular basis of the synergistic effects of *α*Syn, p-tau, A*β*, and other pathologic proteins, suggesting a dualism or triad of neurodegeneration, are a major challenge for modern neuroscience. Improved understanding of these mechanisms may not only improve our insight into the pathogenesis of proteinopathies, but also have an impact on diagnostic and therapeutic possibilities.
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